Delivering Therapy Where it Matters
Developing Innovative Therapy For Targeted Treatment of Difficult-to-Treat Cancers
The Phase III TIGeR-PaC clinical trial is a randomized multi-center study using RenovoRx’s innovative therapy platform, RenovoTAMP® (RenovoRx Trans-arterial Micro-perfusion), to evaluate RenovoRx’s first product candidate, RenovoGem™, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (an FDA-approved chemotherapy). The goal of the study has a primary endpoint of overall survival and several secondary endpoints, including quality of life.
TIGeR-PaC is currently enrolling locally advanced, unresectable LAPC patients.
RenovoTAMP is an innovative therapy platform designed for targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors, intending to decrease the systemic effects typical of these drugs and increase local drug concentration. The goals of RenovoTAMP are to improve the quality of life for patients battling difficult-to-treat cancers, as well as to extend their survival.
RenovoRx’s lead product candidate is RenovoGem (gemcitabine, an FDA-approved chemotherapy, delivered via our patented delivery system and regulated by the FDA as a novel oncology drug product). RenovoGem utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via the RenovoTAMP therapy platform. RenovoGem is currently being evaluated in a Phase III clinical trial in Locally Advanced Pancreatic Cancer (LAPC) patients and RenovoRx plans to investigate RenovoGem in extrahepatic Cholangiocarcinoma (eCCA) in a Phase II trial beginning in the first half 2023.
RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Our mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial ( IA) delivery of chemotherapy directly to solid tumors. The RenovoTAMP therapy platform is being investigated to avoid the harsh side effects typical of the current standard of care, improving patient well-being and extension of life so more time can be enjoyed with loved ones.